Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy

@article{Valenzano2005PharmacologicalAP,
  title={Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy},
  author={K. Valenzano and Laykea Tafesse and G. Lee and J. Harrison and G. Whiteside},
  journal={Neuropharmacology},
  year={2005},
  volume={48},
  pages={658-672}
}
  • K. Valenzano, Laykea Tafesse, +2 authors G. Whiteside
  • Published 2005
  • Chemistry, Medicine
  • Neuropharmacology
  • To date, two cannabinoid receptors have been identified, CB1 and CB2. Activation of these receptors with non-selective cannabinoid receptor agonists reduces pain sensitivity in animals and humans. However, activation of CB1 receptors is also associated with central side effects, including ataxia and catalepsy. More recently, a role for selective CB2 agonists in pain modification has been demonstrated. GW405833, a selective CB2 agonist, was recently reported to partially reverse the inflammation… CONTINUE READING
    Cannabinoid CB2 Agonist GW405833 Suppresses Inflammatory and Neuropathic Pain through a CB1 Mechanism that is Independent of CB2 Receptors in Mice
    • 14
    • Highly Influenced
    • PDF
    CB1 cannabinoid receptor antagonism for treating inflammation and arthritis
    • 2

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 39 REFERENCES